SciELO - Scientific Electronic Library Online

 
vol.37 número3Respuesta inmunológica y bioquímica de ancianos con infección urinaria frente factores de virulencia en Escherichia coli uropatógenasLos retos del cuidado de las personas con diabetes durante el estado de emergencia nacional por COVID-19 en Lima, Perú: recomendaciones para la atención primaria índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Peruana de Medicina Experimental y Salud Publica

versão impressa ISSN 1726-4634

Resumo

SECCO, Anastasia; ALFIE, Verónica; ESPINOLA, Natalia  e  BARDACH, Ariel. Epidemiology, resource use and costs of rheumatoid arthritis in Argentina. Rev. perú. med. exp. salud publica [online]. 2020, vol.37, n.3, pp.532-540. ISSN 1726-4634.  http://dx.doi.org/10.17843/rpmesp.2020.373.4766.

This review aims to identify information on epidemiological parameters and estimate the cost of moderate to severe rheumatoid arthritis (RA). A search for related literature was carried out in major databases. A consensus of local rheumatology experts was used to find the most realistic parameters, using a modified Delphi method. Direct medical costs were estimated, using information collected from the cost per unit database of the Instituto de Efectividad Clínica y Sanitaria de Argentina. Indirect costs were estimated using the human resources approach. Costs were expressed in US dollars (USD) as of November 2017. The reported prevalence of RA in Argentina was 0.94% (95%CI: 0.86 to 1.02), with an annual incidence rate of 19 per 100,000 people (95%CI: 17 to 20). The annual cost of disease-modifying drugs was 33,936.10 USD per patient. The cost attributed to serious infections was 2,474.6 USD. The cost of bilateral knee replacement per patient was $5,276.8 USD; and the cost for total hip replacement was $9,196.4. Both, the cost of hospitalization days per patient per year, and the indirect costs of RA increased as the disability score increased. This review reports useful information on epidemiological and cost parameters of moderate to severe RA, in the era of biological agents, in order to be useful for conducting economic evaluations regarding health in Argentina.

Palavras-chave : Arthritis; Rheumatoid; Disabled Persons; Antirheumatic Agents; Health Care Costs; Argentina.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )